Physician profile
Jason E Clay
NPI 1912570292
$3,072.96
in general payments reported to CMS, 2019-2025
32 companies · $1,465 in 2025
The $1,465 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.77 · 2022: $169 · 2023: $614 · 2024: $788 · 2025: $1,465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,867.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,867.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $586.45 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $541.03 | 2022-2025 | |
| Lilly USA, LLC | $284.19 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Axsome Therapeutics, INC. | $246.99 | 2024-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $161.47 | 2024-2025 | Airsupra, Breztri |
| Inspire Medical Systems, INC. | $148.44 | 2024-2025 | Inspire |
| Vanda Pharmaceuticals INC. | $113.17 | 2025 | Fanapt |
| Lundbeck LLC | $107.75 | 2024-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $96.81 | 2022-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.16 | 2023-2025 | Jardiance |
| Amgen INC. | $78.49 | 2023-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $67.42 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $56.09 | 2025 | Spravato |
| Antares Pharma, INC. | $46.09 | 2023 | Nocdurna, Tlando, Xyosted |
| Astellas Pharma US INC | $43.34 | 2024-2025 | Veozah |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $41.39 | 2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $38.91 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Medical Device Business Services, INC. | $36.77 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.66 | 2025 | Caplyta |
| Pfizer INC. | $30.48 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.42 | 2023-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $27.20 | 2022-2025 | |
| Organon LLC | $26.22 | 2025 | Nexplanon |
| Takeda Pharmaceuticals U.S.A., INC. | $19.84 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.20 | 2023 | Leqvio |
| Sumitomo Pharma America, INC. | $19.06 | 2025 | Gemtesa |
| Medtronic, INC. | $17.98 | 2022 | |
| Neurocrine Biosciences, INC. | $17.01 | 2025 | |
| Shield Therapeutics INC | $14.92 | 2024 | |
| Halozyme INC | $13.16 | 2023 | |
| Therapeuticsmd, INC. | $13.08 | 2022 | |
| Corium, LLC | $10.77 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Clay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.